British Association of Dermatologists’ guidelines for the management of contact dermatitis 2017
G.A. Johnston(University Hospitals of Leicester NHS Trust), L.S. Exton(British Association of Dermatologists), F.S. Worsnop, L.S. Exton(British Association of Dermatologists), J. Natkunarajah, Michael J. Cork(University of Sheffield), S. Ungureanu, P.M. McHenry, S. H. Wakelin, A.G. Brain, D.A. Buckley, T.A. Leslie, R.Y.P. Hunasehally, John English(University of Nottingham), Clare Saunders(Manchester Academic Health Science Centre), Karen Gibbon, Nicholas Chiang, Eleanor Mallon, J.F. BOURKE(South Infirmary Victoria University Hospital), J. Slack(University Hospitals of Leicester NHS Trust), I. H. Coulson(Burnley General Teaching Hospital), J. Donnelly, M.F. Mohd Mustapa(British Association of Dermatologists)
Cited by 83
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Epidermal Barrier Dysfunction in Atopic Dermatitis
|Journal of Investigative Dermatology|2009|756
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
|Journal of the American Academy of Dermatology|2020|385